ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19
Natalie S Grover, Nicholas Tschernia, Gianpietro Dotti, Barbara Savoldo
Abstract readReview
In one paragraphReview in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
4 authors.
Natalie S GroverLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0002-1346-3157 Nicholas TscherniaLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0002-2389-9974 Gianpietro DottiLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
Barbara SavoldoLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0002-7571-3887 Funding
UNC Oncology K12K12CA120780 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WILLIAM Y. KIM · 2007 to 2026
$9.6MEnhancing cell therapy for brain tumorsU01CA239258 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI BOLLARD, CATHERINE M., CRUZ, CONRAD RUSSELL YOUNG · 2018 to 2022
$3.2MTailoring CAR T cell therapy for Hodgkin LymphomaR01CA247497 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SAVOLDO, BARBARA · 2020 to 2024
$3.1MTargeting the Ig-light chains with CAR-T cells in lymphoid tumorsR01CA193140 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DOTTI, GIANPIETRO · 2016 to 2020
$2.7MDuke-UNC Chapel Hill Immunotherapy Training GrantT32CA211056 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHAO, NELSON J., SERODY, JONATHAN S. · 2017 to 2021
$2.2MCellular Immunotherapy of Ovarian CancerR01CA243543 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DOTTI, GIANPIETRO · 2019 to 2023
$2.0MTargeting and Delivering CAR-Ts in GlioblastomaR21CA229938 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DOTTI, GIANPIETRO · 2019 to 2020
$372kNCI NIH HHS K12 CA120780NCI NIH HHS R01 CA193140NCI NIH HHS R01 CA243543NCI NIH HHS R01 CA247497NCI NIH HHS R21 CA229938NCI NIH HHS T32 CA211056NCI NIH HHS U01 CA239258
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antigens, CD19B-LymphocytesClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicHematologic NeoplasmsHumansImmunotherapy, AdoptiveAntigens, CD19CD19 molecule, human
Identifiers
PMID33434072
PMCPMC8462586
What OpenQuestion holds
Textmetadata
Read underepoch 390